The FDA has approved pritelivir to treat mucocutaneous lesions caused by herpes simplex virus in immunocompromised adult ...

The FDA has approved pritelivir (Hovilpri) tablets for adults with weakened immune systems who have mucocutaneous lesions ...

Oct 9 (Reuters) - The US FDA on Friday approved Japan's Asahi Kasei's drug for persistent herpes simplex virus sores in ...

New research reveals how the forever chemical PFOS disrupts a key immune protein, allowing flu and other viruses to multiply ...

Simplex Castings issued a corrigendum to correct allottee names in its EGM notice. Promoter Ketan Moolchand Shah's stake will ...

A new meta-analysis of randomized trials and observational studies finds no clear benefit or harm from adjunctive ...

Pritelivir (Hovilpri) healed all lesions by day 28 in 63% of immunocompromised adults with refractory HSV versus 34% with investigator's choice in the phase 3 PRIOH-1 trial. The FDA has approved ...

A Colombian study of 478 patients found that routine cerebrospinal fluid white cell counts and protein levels could predict ...

The FDA approved Hovilpri for herpes lesions that do not respond to other antivirals in immunocompromised adults. In a trial, 63% achieved complete healing.

Renley's incurable condition isn't the result of an inherited gene but a more unusual and much rarer set of circumstances.

Some order wins are about the money, and others are about a company getting back to doing what it knows best. A century-old ...

She described the patient consult as the starting point for aesthetic care. It covers the patient’s history, motivation for seeking treatment, prior aesthetic procedures, keloid history, and herpes ...